Aquestive Therapeutics (AQST) News Today $6.54 -0.15 (-2.24%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$6.56 +0.03 (+0.38%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AQST Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Aquestive Therapeutics: A Measured BetOctober 12 at 4:02 AM | seekingalpha.comAquestive Therapeutics (NASDAQ:AQST) Hits New 12-Month High - Should You Buy?October 11 at 6:19 AM | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Shares Up 7% - Still a Buy?October 10 at 7:48 PM | marketbeat.comJMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform RecommendationOctober 10 at 10:39 AM | msn.comWeiss Ratings Reiterates Sell (D-) Rating for Aquestive Therapeutics (NASDAQ:AQST)October 9, 2025 | marketbeat.comAquestive gains after new patent wins for AnaphylmOctober 9, 2025 | msn.comAquestive Therapeutics Secures New Patents for Anaphylm™ Sublingual Film, Extending Protection Through 2037October 8, 2025 | quiverquant.comQAquestive Therapeutics Broadens Patent Estate for Anaphylm™October 8, 2025 | globenewswire.comAquestive Therapeutics (NASDAQ:AQST) Insider Peter Boyd Sells 10,000 SharesSeptember 30, 2025 | insidertrades.comPeter Boyd Sells 10,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) StockSeptember 29, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) CEO Sells $550,798.29 in StockSeptember 29, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Trading Down 5.3% After Insider SellingSeptember 29, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Hits New 52-Week High - Time to Buy?September 26, 2025 | marketbeat.comA Look at Aquestive Therapeutics’s Valuation Following Positive FDA Update on AnaphylmSeptember 24, 2025 | finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Trading 9% Higher - Here's What HappenedSeptember 23, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Trading Down 7% - Time to Sell?September 22, 2025 | marketbeat.comJim Cramer on Aquestive Therapeutics: “I think it’s Worth Taking a Chance On”September 22, 2025 | insidermonkey.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Buy" by AnalystsSeptember 22, 2025 | marketbeat.comAquestive Therapeutics (AQST) Is Up 12.3% After FDA Waives Panel for Oral Epinephrine ApplicationSeptember 21, 2025 | finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Reaches New 12-Month High - Still a Buy?September 20, 2025 | marketbeat.comStock Traders Purchase Large Volume of Call Options on Aquestive Therapeutics (NASDAQ:AQST)September 20, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Shares Up 5.2% - Here's What HappenedSeptember 14, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) COO Sells $310,900.00 in StockSeptember 10, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Insider Peter Boyd Sells 15,000 SharesSeptember 10, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Shares Down 6.4% - Time to Sell?September 10, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $8.00 at OppenheimerSeptember 10, 2025 | marketbeat.comEverstar Asset Management LLC Purchases 83,777 Shares of Aquestive Therapeutics, Inc. $AQSTSeptember 10, 2025 | marketbeat.comAquestive Therapeutics price target raised to $8 from $7 at OppenheimerSeptember 9, 2025 | msn.comPeter Boyd Sells 15,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) StockSeptember 9, 2025 | insidertrades.comAquestive Therapeutics, Inc. (AQST) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 9, 2025 | seekingalpha.comQ3 Earnings Forecast for AQST Issued By Lifesci CapitalSeptember 7, 2025 | marketbeat.comAquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade)September 6, 2025 | seekingalpha.comLifesci Capital Upgrades Aquestive Therapeutics (NASDAQ:AQST) to Strong-BuySeptember 6, 2025 | marketbeat.comNuveen LLC Makes New $686,000 Investment in Aquestive Therapeutics, Inc. $AQSTSeptember 6, 2025 | marketbeat.comAquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval CatalystSeptember 5, 2025 | seekingalpha.comFDA Confirms Direct Review Path For Aquestive's Allergy TreatmentSeptember 4, 2025 | finance.yahoo.comAquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™September 4, 2025 | markets.businessinsider.comAquestive jumps as FDA says no AdCom for allergy therapy AnaphylmSeptember 4, 2025 | msn.comAquestive Therapeutics initiated with an Outperform at LifeSci CapitalSeptember 3, 2025 | msn.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 30, 2025 | marketbeat.comAquestive Therapeutics to Participate in Upcoming September Investor ConferencesAugust 26, 2025 | finance.yahoo.comPale Fire Capital SE Has $3.87 Million Position in Aquestive Therapeutics, Inc. $AQSTAugust 26, 2025 | marketbeat.comPenn Capital Management Company LLC Buys New Holdings in Aquestive Therapeutics, Inc. $AQSTAugust 26, 2025 | marketbeat.comFY2025 EPS Estimates for AQST Boosted by Cantor FitzgeraldAugust 23, 2025 | marketbeat.comAquestive signs $75m agreement for launch of AnaphylmAugust 19, 2025 | msn.comFY2025 EPS Estimates for AQST Increased by Cantor FitzgeraldAugust 17, 2025 | marketbeat.comLeerink Partnrs Has Positive Forecast for AQST Q3 EarningsAugust 17, 2025 | marketbeat.comAquestive Therapeutics announces $75M strategic funding agreement with RTWAugust 15, 2025 | msn.comAquestive Therapeutics Announces $85M Stock OfferingAugust 15, 2025 | msn.comAquestive Therapeutics stock rises after securing $75 million funding dealAugust 14, 2025 | investing.com Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Videos AQST Media Mentions By Week AQST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.940.77▲Average Medical News Sentiment AQST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼105▲AQST Articles Average Week Get the Latest News and Ratings for AQST and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aquestive Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies DNLI News SRPT News ETNB News TVTX News ADPT News NTLA News OCUL News ANIP News VERA News TWST News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
